Anti-GMR CAR T-cell Therapy

N/A

Report date: 2024/08/02 18:02:09

Base Information

Drug NameAnti-GMR CAR T-cell Therapy
Drug Alias NameAnti-CD116 CAR T-cell Therapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionGranulocyte-macrophage colony-stimulating factor receptor subunit alpha modulators
TargetsGranulocyte-macrophage colony-stimulating factor receptor subunit alpha
Therapy Area/IndicationsLeukemia, Myelomonocytic, JuvenileLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesKyoto Prefectural University Of MedicineShinshu University School of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesShinshu University School of Medicine
Inactive CompaniesN/A
Active IndicationsLeukemia, Myelomonocytic, JuvenileLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A